DoW Melanoma Research Program Melanoma Academy Scholar Award
Dept. of Defense — CDMRP · Other Federal · HT942526MRPMASA
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- $1.5M total
- DeadlineFinal application due date.
- Oct 14, 2026
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- —
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- 2
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- Unknown
- Open dateWhen applications open (or opened).
- May 21, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $1.5M total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Unspecified
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
Summary: Supports the addition of independent, early career investigators (Scholars) who are no more than seven years from their initial faculty appointment to the Melanoma Research Program (MRP) Melanoma Academy. The Melanoma Academy is a unique, interactive virtual academy focused on bringing together established investigators and Scholars to develop a network of successful, highly productive melanoma researchers in a collaborative research and career development environment. Distinctive Features: This award mechanism focuses on both the Scholar’s research and career potential in the melanoma field. Scholars must designate a Career Guide. The Career Guide must have a track record of successful mentorship coupled with a strong record of funding and publications in melanoma. Preliminary data are not required.